Decreased parvalbumin mRNA expression in dorsolateral prefrontal cortex in Parkinson′s disease

Brain Research

Volumn 1531, Issue , 2013, Pages 37-47

  Lanoue, Amélie C ^a   Blatt, Gene J ^a   Soghomonian, Jean Jacques ^a  

^a Department of Anatomy and Neurobiology ^*  (United States)

Author keywords

GABA; Gene expression; mRNA; Parkinson s disease; Parvalbumin; Prefrontal cortex

Indexed keywords

MESSENGER RNA; PARVALBUMIN;

ARTICLE; CELL LEVEL; CONTROLLED STUDY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERNEURON; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEREOLOGY; TISSUE SECTION;

GABA; GENE EXPRESSION; MRNA; PARKINSON′S DISEASE; PARVALBUMIN; PREFRONTAL CORTEX;

ADULT; AGED; AGED, 80 AND OVER; CELL COUNT; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MIDDLE AGED; NEURONS; PARKINSON DISEASE; PARVALBUMINS; PREFRONTAL CORTEX; RNA, MESSENGER;

EID: 84883286122     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.07.025     Document Type: Article

References (66)

1. C.R. Arthur, S.L. Morton, L.D. Dunham, P.M. Keeney, and J.P. Bennett Jr. Parkinson′s disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance Mol. Neurodegener. 4 2009 37
2. M. Bares, P. Kanovsky, H. Klajblova, and I. Rektor Intracortical inhibition and facilitation are impaired in patients with early Parkinson′s disease: a paired TMS study Eur. J. Neurol. 10 2003 385 389
3. M. Bartos, I. Vida, and P. Jonas Synaptic mechanisms of synchronized gamma oscillations in inhibitory interneuron networks Nat. Rev. Neurosci. 8 2007 45 56
4. C.L. Beasley, Z.J. Zhang, I. Patten, and G.P. Reynolds Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins Biol. Psychiatry. 52 2002 708 715
5. F.M. Benes, and S. Berretta GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder Neuropsychopharmacology 25 2001 1 27
6. H. Braak, E. Ghebremedhin, U. Rub, H. Bratzke, and K. Del Tredici Stages in the development of Parkinson′s disease-related pathology Cell Tissue Res. 318 2004 121 134
7. H. Bueler Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson′s disease Exp. Neurol. 218 2009 235 246
8. C. Buhmann, V. Glauche, H.J. Sturenburg, M. Oechsner, C. Weiller, and C. Buchel Pharmacologically modulated fMRI - cortical responsiveness to levodopa in drug-naive hemiparkinsonian patients Brain 126 2003 451 461
9. R. Cantello, R. Tarletti, and C. Civardi Transcranial magnetic stimulation and Parkinson′s disease Brain Res. Brain Res. Rev. 38 2002 309 327
10. V.S. Catts, S.V. Catts, H.R. Fernandez, J.M. Taylor, E.J. Coulson, and L.H. Lutze-Mann A microarray study of post-mortem mRNA degradation in mouse brain tissue Brain Res.: Mol Brain Res. 138 2005 164 177
11. T. Collin, M. Chat, M.G. Lucas, H. Moreno, P. Racay, and B. Schwaller Developmental changes in parvalbumin regulate presynaptic Ca2+ signaling J. Neurosci. 25 2005 96 107
12. R.M. Costa, S.C. Lin, T.D. Sotnikova, M. Cyr, R.R. Gainetdinov, M.G. Caron, and M.A. Nicolelis Rapid alterations in corticostriatal ensemble coordination during acute dopamine-dependent motor dysfunction Neuron 52 2006 359 369
13. K.H. Cox, D.V. DeLeon, L.M. Angerer, and R.C. Angerer Detection of mrnas in sea urchin embryos by in situ hybridization using asymmetric RNA probes Dev. Biol. 101 1984 485 502
14. D.C. Duke, L.B. Moran, M.E. Kalaitzakis, M. Deprez, D.T. Dexter, R.K. Pearce, and M.B. Graeber Transcriptome analysis reveals link between proteasomal and mitochondrial pathways in Parkinson′s disease Neurogenetics 7 2006 139 148
15. S. Feldblum, M.G. Erlander, and A.J. Tobin Different distributions of GAD65 and GAD67 mRNAs suggest that the two glutamate decarboxylases play distinctive functional roles J. Neurosci. Res. 34 1993 689 706
16. K.N. Fish, R.A. Sweet, and D.A. Lewis Differential distribution of proteins regulating GABA synthesis and reuptake in axon boutons of subpopulations of cortical interneurons Cereb. Cortex 21 2011 2450 2460
17. T.F. Freund, and I. Katona Perisomatic inhibition Neuron 56 2007 33 42
18. T. Fukuda, J. Takahashi, and J. Tanaka Tyrosine hydroxylase- immunoreactive neurons are decreased in number in the cerebral cortex of Parkinson′s disease Neuropathology 19 1999 10 13
19. A. Galvan, and T. Wichmann Pathophysiology of parkinsonism Clin. Neurophysiol. 119 2008 1459 1474
20. P. Gaspar, C. Duyckaerts, C. Alvarez, F. Javoy-Agid, and B. Berger Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson′s disease Ann. Neurol. 30 1991 365 374
21. H.J. Gundersen, P. Bagger, T.F. Bendtsen, S.M. Evans, L. Korbo, N. Marcussen, A. Moller, K. Nielsen, J.R. Nyengaard, and B. Pakkenberg The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis Apmis 96 1988 857 881
22. H.J. Gundersen, E.B. Jensen, K. Kieu, and J. Nielsen The efficiency of systematic sampling in stereology - reconsidered J. Microsc. 193 1999 199 211
23. R. Hanajima, and Y. Ugawa Intracortical inhibition of the motor cortex in movement disorders Brain Dev. 22 Suppl 1 2000 S132 S135
24. P.J. Harrison, P.R. Heath, S.L. Eastwood, P.W. Burnet, B. McDonald, and R.C. Pearson The relative importance of premortem acidosis and postmortem interval for human brain gene expression studies: selective mRNA vulnerability and comparison with their encoded proteins Neurosci. Lett. 200 1995 151 154
25. B. Haslinger, P. Erhard, N. Kampfe, H. Boecker, E. Rummeny, M. Schwaiger, B. Conrad, and A.O. Ceballos-Baumann Event-related functional magnetic resonance imaging in Parkinson′s disease before and after levodopa Brain 124 2001 558 570
26. N. Ibarretxe-Bilbao, B. Ramirez-Ruiz, C. Junque, M.J. Marti, F. Valldeoriola, N. Bargallo, S. Juanes, and E. Tolosa Differential progression of brain atrophy in Parkinson′s disease with and without visual hallucinations J. Neurol. Neurosurg. Psychiatry 81 2010 650 657
27. I.H. Jenkins, W. Fernandez, E.D. Playford, A.J. Lees, R.S. Frackowiak, R.E. Passingham, and D.J. Brooks Impaired activation of the supplementary motor area in Parkinson′s disease is reversed when akinesia is treated with apomorphine Ann. Neurol. 32 1992 749 757
28. A. Kashani, C. Betancur, B. Giros, E. Hirsch, and S. El Mestikawy Altered expression of vesicular glutamate transporters VGLUT1 and VGLUT2 in Parkinson disease Neurobiol. Aging 28 2007 568 578
29. A. Kikuchi, A. Takeda, T. Kimpara, M. Nakagawa, R. Kawashima, M. Sugiura, S. Kinomura, H. Fukuda, K. Chida, N. Okita, S. Takase, and Y. Itoyama Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson′s disease J. Neurol. Sci. 193 2001 29 36
30. A.E. Kingsbury, O.J. Foster, A.P. Nisbet, N. Cairns, L. Bray, and D.J. Eve Tissue pH as an indicator of mRNA preservation in human post-mortem brain Brain Res.: Mol. Brain Res. 28 1995 311 318
31. J.W. Kinney, C.N. Davis, I. Tabarean, B. Conti, T. Bartfai, and M.M. Behrens A specific role for NR2A-containing NMDA receptors in the maintenance of parvalbumin and GAD67 immunoreactivity in cultured interneurons J. Neurosci. 26 2006 1604 1615
32. A.C. Lanoue, A. Dumitriu, R.H. Myers, and J.J. Soghomonian Decreased glutamic acid decarboxylase mRNA expression in prefrontal cortex in Parkinson′s disease Exp. Neurol. 226 2010 207 217
33. J.P. Lefaucheur Motor cortex dysfunction revealed by cortical excitability studies in Parkinson′s disease: influence of antiparkinsonian treatment and cortical stimulation Clin. Neurophysiol. 116 2005 244 253
34. D.A. Lewis, T. Hashimoto, and D.W. Volk Cortical inhibitory neurons and schizophrenia Nat. Rev. Neurosci. 6 2005 312 324
35. D.A. Lewis, A.A. Curley, J.R. Glausier, and D.W. Volk Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia Trends Neurosci. 35 2012 57 67
36. N. Lindefors, S. Brene, M. Herrera-Marschitz, and H. Persson Region specific regulation of glutamic acid decarboxylase mRNA expression by dopamine neurons in rat brain Exp. Brain Res. 77 1989 611 620
37. C.H. Lyoo, Y.H. Ryu, and M.S. Lee Topographical distribution of cerebral cortical thinning in patients with mild Parkinson′s disease without dementia Mov. Disord. 25 2010 496 499
38. V. MacDonald, and G.M. Halliday Selective loss of pyramidal neurons in the pre-supplementary motor cortex in Parkinson′s disease Mov. Disord. 17 2002 1166 1173
39. T.R. Melzer, R. Watts, M.R. MacAskill, T.L. Pitcher, L. Livingston, R.J. Keenan, J.C. Dalrymple-Alford, and T.J. Anderson Grey matter atrophy in cognitively impaired Parkinson′s disease J. Neurol. Neurosurg. Psychiatry 83 2012 188 194
40. L.B. Moran, D.C. Duke, M. Deprez, D.T. Dexter, R.K. Pearce, and M.B. Graeber Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson′s disease Neurogenetics 7 2006 1 11
41. P. Mouton Principles and practices of unbiased stereology: an introduction for bioscientists 2002 The Johns Hopkins University Press Baltimore and London
42. 2+ buffer in the calyx of held that accelerates the decay of Ca2+ and short-term facilitation J. Neurosci. 27 2007 2261 2271
43. K. Nakashima, Y. Wang, M. Shimoda, K. Sakuma, and K. Takahashi Shortened silent period produced by magnetic cortical stimulation in patients with Parkinson′s disease J. Neurol. Sci. 130 1995 209 214
44. A. Navarro, A. Boveris, M.J. Bandez, M.J. Sanchez-Pino, C. Gomez, G. Muntane, and I. Ferrer Human brain cortex: mitochondrial oxidative damage and adaptive response in Parkinson disease and in dementia with Lewy bodies Free Radic. Biol. Med. 46 2009 1574 1580
45. S. Nikolaus, C. Antke, and H.W. Muller In vivo imaging of synaptic function in the central nervous system: I. Movement disorders and dementia Behav. Brain Res. 204 2009 1 31
46. Y. Nishio, K. Hirayama, A. Takeda, Y. Hosokai, T. Ishioka, K. Suzuki, Y. Itoyama, S. Takahashi, and E. Mori Corticolimbic gray matter loss in Parkinson′s disease without dementia Eur. J. Neurol. 17 2010 1090 1097
47. W.D. Parker Jr., J.K. Parks, and R.H. Swerdlow Complex I deficiency in Parkinson′s disease frontal cortex Brain Res. 1189 2008 215 218
48. K.M. Pedersen, L. Marner, H. Pakkenberg, and B. Pakkenberg No global loss of neocortical neurons in Parkinson′s disease: a quantitative stereological study Mov. Disord. 20 2005 164 171
49. M. Petrides, and D.N. Pandya Dorsolateral prefrontal cortex: comparative cytoarchitectonic analysis in the human and the macaque brain and corticocortical connection patterns Eur. J. Neurosci. 11 1999 1011 1036
50. E.D. Playford, I.H. Jenkins, R.E. Passingham, J. Nutt, R.S. Frackowiak, and D.J. Brooks Impaired mesial frontal and putamen activation in Parkinson′s disease: a positron emission tomography study Ann. Neurol. 32 1992 151 161
51. A. Priori, A. Berardelli, M. Inghilleri, N. Accornero, and M. Manfredi Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson′s disease and drug-induced parkinsonism Brain 117 Pt 2 1994 317 323
52. G. Rajkowska, and P.S. Goldman-Rakic Cytoarchitectonic definition of prefrontal areas in the normal human cortex: I. Remapping of areas 9 and 46 using quantitative criteria Cereb. Cortex. 5 1995 307 322
53. B. Ramirez-Ruiz, M.J. Marti, E. Tolosa, D. Bartres-Faz, C. Summerfield, P. Salgado-Pineda, B. Gomez-Anson, and C. Junque Longitudinal evaluation of cerebral morphological changes in Parkinson′s disease with and without dementia J. Neurol. 252 2005 1345 1352
54. O. Rascol, U. Sabatini, F. Chollet, N. Fabre, J.M. Senard, J.L. Montastruc, P. Celsis, J.P. Marc-Vergnes, and A. Rascol Normal activation of the supplementary motor area in patients with Parkinson′s disease undergoing long-term treatment with levodopa J. Neurol. Neurosurg. Psychiatry 57 1994 567 571
55. S. Retaux, F. Trovero, and M.J. Besson Role of dopamine in the plasticity of glutamic acid decarboxylase messenger RNA in the rat frontal cortex and the nucleus accumbens Eur. J. Neurosci. 6 1994 1782 1791
56. G.P. Reynolds, and C.L. Beasley GABAergic neuronal subtypes in the human frontal cortex - development and deficits in schizophrenia J. Chem. Neuroanat. 22 2001 95 100
57. M.C. Ridding, R. Inzelberg, and J.C. Rothwell Changes in excitability of motor cortical circuitry in patients with Parkinson′s disease Ann. Neurol. 37 1995 181 188
58. D.L. Rosene, N.J. Roy, and B.J. Davis A cryoprotection method that facilitates cutting frozen sections of whole monkey brains for histological and histochemical processing without freezing artifact J. Histochem. Cytochem. 34 1986 1301 1315
59. P. Silberstein, A. Pogosyan, A.A. Kuhn, G. Hotton, S. Tisch, A. Kupsch, P. Dowsey-Limousin, M.I. Hariz, and P. Brown Cortico-cortical coupling in Parkinson′s disease and its modulation by therapy Brain 128 2005 1277 1291
60. J.J. Soghomonian, S. Pedneault, G. Audet, and A. Parent Increased glutamate decarboxylase mRNA levels in the striatum and pallidum of MPTP-treated primates J. Neurosci. 14 1994 6256 6265
61. G.T. Sutherland, N.A. Matigian, A.M. Chalk, M.J. Anderson, P.A. Silburn, A. Mackay-Sim, C.A. Wells, and G.D. Mellick A cross-study transcriptional analysis of Parkinson′s disease PLoS One 4 2009 e4955
62. C. Tessa, C. Lucetti, S. Diciotti, L. Paoli, P. Cecchi, M. Giannelli, F. Baldacci, A. Ginestroni, C. Vignali, M. Mascalchi, and U. Bonuccelli Hypoactivation of the primary sensorimotor cortex in de novo Parkinson′s disease: a motor fMRI study under controlled conditions Neuroradiology 54 2012 261 268
63. M. Vreugdenhil, J.G. Jefferys, M.R. Celio, and B. Schwaller Parvalbumin-deficiency facilitates repetitive IPSCs and gamma oscillations in the hippocampus J. Neurophysiol. 89 2003 1414 1422
64. D. Weintraub, J. Doshi, D. Koka, C. Davatzikos, A.D. Siderowf, J.E. Duda, D.A. Wolk, P.J. Moberg, S.X. Xie, and C.M. Clark Neurodegeneration across stages of cognitive decline in Parkinson disease Arch. Neurol. 68 2011 1562 1568
65. Y. Zhang, M. James, F.A. Middleton, and R.L. Davis Transcriptional analysis of multiple brain regions in Parkinson′s disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms Am. J. Med. Genet. B Neuropsychiatry Genet. 137B 2005 5 16
66. U. Ziemann, S. Lonnecker, B.J. Steinhoff, and W. Paulus The effect of lorazepam on the motor cortical excitability in man Exp. Brain Res. 109 1996 127 135